COMMUNIQUÉS West-GlobeNewswire

STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
21/04/2026
DUBLIN, IRELAND, April 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 fourth quarter and full year results [...]
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
21/04/2026
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior [...]
Intuitive Announces First Quarter Earnings
21/04/2026
SUNNYVALE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced [...]
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
21/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 [...]
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentations Data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal [...]
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
21/04/2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 [...]
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
21/04/2026
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum [...]
Panakeia Unveils Landmark Metabolic and Pathway Activation Data in Cancers at AACR 2026
21/04/2026
CAMBRIDGE, UK — April 21, 2026 — Panakeia (“the Company”), the world’s first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research ( [...]
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
21/04/2026
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer REDWOOD [...]
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Bronson Methodist Hospital Named No. 1 Academic Medical Center in the Nation; Earns Premier 100 Top Hospital® Honor
21/04/2026
KALAMAZOO, Mich., April 21, 2026 (GLOBE NEWSWIRE) -- Bronson Methodist Hospital is one of the nation’s 100 Top Hospitals® and the top Academic Medical Center in the U.S., according to an independent quality analysis [...]
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform
21/04/2026
Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) [...]
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
21/04/2026
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) MOGAD is a rare autoimmune disease of the central nervous system characterised [...]
Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For”
21/04/2026
Santa Rosa Nonprofit Earns National Recognition for Exceptional Workplace Culture and Employee Experience SANTA ROSA, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , a nonprofit supporting adults with [...]
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
21/04/2026
Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage [...]
ACTG Launches Critical Study Evaluating Hormone Therapy for Women Living with HIV in the Menopause Transition
21/04/2026
CHAPEL HILL, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the HoT study (Menopausal Hormone Therapy for [...]
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04/2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, 2026 (GLOBE [...]
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present [...]

Pages